Other Corporate Information – Page 19

2018-10-30

Regulatory

Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144

New candidate drug selected – the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144 Lund, Sweden, October 30, 2018 – Alligator Bi ...

2018-10-05

Lund, Sweden, October 5, 2018 – Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2018-09-28

Regulatory

Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...

2018-08-30

Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...

2018-07-19

Regulatory

Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-06-25

To read the whole magazine, open the PDF-file at the bottom of this email.

2018-06-21

– Further preclinical findings support a best-in-class profile – Oral presentation at World Preclinical Congress, ...

2018-05-29

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 29, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...

2018-05-16

Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 16, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...